Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Timo Kahles
Long-Term Evaluation of NEDA-3 Status in Relapsing-Remitting Multiple Sclerosis Patients After Switching From Natalizumab to Fingolimod
Therapeutic Advances in Neurological Disorders
Neurology
Pharmacology
Related publications
Predictors for Multiple Sclerosis Relapses After Switching From Natalizumab to Fingolimod
Multiple Sclerosis
Neurology
Efficacy of Natalizumab and Fingolimod in Relapsing Remitting Multiple Sclerosis in Real World Clinical Setting
Journal of Neurology & Neurophysiology
Long-Term Safety and Efficacy of Natalizumab in Relapsing-Remitting Multiple Sclerosis: Impact on Quality of Life
Patient Related Outcome Measures
Natalizumab: A New Treatment for Relapsing Remitting Multiple Sclerosis
Therapeutics and Clinical Risk Management
Chemical Health
Pharmacology
Safety
Medicine
Toxicology
Safety Research
Pharmaceutics
Fingolimod Treatment in Relapsing-Remitting Multiple Sclerosis Patients: A Prospective Observational Multicenter Postmarketing Study
Multiple Sclerosis International
Neurology
Long-Term Safety and Real-World Effectiveness of Fingolimod in Relapsing Multiple Sclerosis
Patient Related Outcome Measures
Extensive Multiple Sclerosis Reactivation After Switching From Fingolimod to Rituximab
Case Reports in Neurological Medicine
Fingolimod and CSF Neurofilament Light Chain Levels in Relapsing-Remitting Multiple Sclerosis
Neurology
Neurology
Correction To: Long-Term Effect of Immediate Versus Delayed Fingolimod Treatment in Young Adult Patients With Relapsing–Remitting Multiple Sclerosis: Pooled Analysis From the FREEDOMS/FREEDOMSII Trials
Neurology and Therapy
Neurology
